Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study

@article{Michelis2016DurationOF,
  title={Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study},
  author={Fotios V Michelis and Eshetu G Atenafu and Stephen Couban and Justin Frazer and Sudeep Pappur Shivakumar and Donna Hogge and Cynthia L Toze and W Rajkhan and H S J Kim and Andrew Daly and Jiri Slaby and J{\"u}rgen M Finke and Thomas Kiss and Christopher N. Bredeson and Mitchell Sabloff and Dawn Sheppard and M. Asem Bakkar and Mats Brune and Donna Wall and Kim Paulson and Gizelle Popradi and Isabeau Walker and Hans A. Messner},
  journal={Bone Marrow Transplantation},
  year={2016},
  volume={51},
  pages={1019-1021}
}
Disease relapse post remission is a major predictor of poor outcome for patients with AML. The relapse rates range from 40% for patients with favorable cytogenetic abnormalities at diagnosis to 90% for patients with adverse cytogenetics. Patients who relapse respond heterogeneously to salvage treatment. Long-term disease control may be achieved by allogenic… CONTINUE READING